BLU945 CAS No.:2660250-10-0

BLU945 CAS No.:2660250-10-0: A Revolutionary Product for the Modern World

BLU945 CAS No.:2660250-10-0 is a highly innovative and revolutionary product that has been manufactured by our company in China. The product offers numerous benefits and advantages that make it an ideal choice for merchants looking to expand their product portfolio and offer their customers something unique and valuable.

BLU945 CAS No.:2660250-10-0 is a highly potent inhibitor of Bruton's tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCγ2), which are integral components of B-cell receptor (BCR) signaling. The product has been shown to exhibit exceptional activity against various hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and many more.

One of the key advantages of BLU945 CAS No.:2660250-10-0 is its exceptional potency and selective activity against BTK and PLCγ2. The product has been shown to have a highly specific mechanism of action, which makes it highly effective in combating hematologic malignancies.

Moreover, BLU945 CAS No.:2660250-10-0 is highly bioavailable and exhibits excellent pharmacokinetic properties. The product has a long half-life and is rapidly absorbed, which makes it an ideal therapeutic agent for both acute and chronic indications.

Another key advantage of BLU945 CAS No.:2660250-10-0 is its excellent safety profile. The product has been extensively studied in preclinical and clinical trials, and has been shown to be well-tolerated and safe in patients. The product has a low incidence of adverse events and side effects, which makes it an ideal choice for patients who are intolerant to other chemotherapeutic agents.

BLU945 CAS No.:2660250-10-0 is a highly versatile product that can be used in a wide range of therapeutic indications. The product has been shown to exhibit exceptional activity against hematologic malignancies, and can be used as a standalone agent or in combination with other chemotherapeutic agents. The product has also been shown to be effective in the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus.

In conclusion, BLU945 CAS No.:2660250-10-0 is a highly innovative and revolutionary product that offers numerous benefits and advantages over other chemotherapeutic agents. The product has a highly specific mechanism of action, is highly bioavailable, and exhibits excellent pharmacokinetic properties. The product is also safe and well-tolerated, with a low incidence of adverse events and side effects. If you are a merchant looking to expand your product portfolio and offer your customers something unique and valuable, BLU945 CAS No.:2660250-10-0 is the perfect choice for you.

Chemical Structure : BLU-945

CAS No.: 2660250-10-0

 

 

 

 

BLU-945 (BLU945)

Catalog No.: URK-V2327 Only Used For Lab.

BLU-945 is a potent, mutant-selective inhibitor of EGFR T790M/C797S and EGFR+/T790M mutations (IC50<1 nM).

Biological Activity

BLU-945 is a potent, mutant-selective inhibitor of EGFR T790M/C797S and EGFR+/T790M mutations (IC50<1 nM).
BLU-945 inhibits EGFRex19del/T790M/C797S, EGFRL858R/T790M/C797S, EGFRex19del/T790M, and EGFRL858R/T790M mutants with sub-nanomolar IC50 values in an enzyme assay, with >1000-fold selectivity over EGFR WT.
BLU-945 achieves potent EGFR pathway inhibition in NCI-H1975 EGFRL858R/T790M, Ba/F3 EGFRL858R/T790M/C797S, and Ba/F3 EGFRex19del/T790M/C797S cell lines and a large window relative to EGFRWT inhibition.
Oral administration of BLU-945 to tumor-bearing mice demonstrated potent EGFR pathway inhibition and anti-tumor activity at well-tolerated doses in the subcutaneous NCI-H1975 CDX model, and osimertinib-resistant CDX and PDX models.

Physicochemical Properties

References

1. Sun Min Lim, et al. Cancer Res (2021) 81 (13_Supplement): 1467.

URK-V2327_COA

URK-V2327_SDS

URK-V2327_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our company has a strong commitment to sustainability and we take great care to minimize our environmental impact.
• We attach great importance to team building, staff quality education and skill training with the guiding ideology of 'being a man in advance'.
• We offer a range of different packaging options for our Tyrosine Kinase Library products to suit the needs of our customers.
• We have stable workshop production, high level sales team and the establishment of the whole industrial chain, highlighting the clear positioning of our business development strategy.
• We take great care to ensure that our Tyrosine Kinase Library products are delivered on time and in perfect condition.
• The company has a complete and scientific quality management system, and has been operating in good faith in many years of development, strictly producing all products, aiming at meeting the needs of customers.
• Our company is a leading supplier and manufacturer of Tyrosine Kinase Library products.
• To ensure quality, our BLU945 CAS No.:2660250-10-0 is rigorously tested and matched before it is packaged and shipped to customers.
• Our Tyrosine Kinase Library products are designed to provide consistent performance, batch after batch.
• We are willing to share the fruits of development with many parties and add a harmonious and win-win momentum to society.

Hot Tags: blu945 cas no.:2660250-10-0, China blu945 cas no.:2660250-10-0, epigenetic library for epigenetic transduction, epigenetic library for epigenetic regulation of cell apoptosis, epigenetic library for epigenetic analysis of epigenetic stability, agonists in pharmaceutical research, inhibitors for sepsis research, nf b pathway metabolomics